Biotron (ASX:BIT) has announced the acquisition of Sedarex, the owner of global patents for SedRx, a next-generation general anaesthetic with the potential to reshape the $6.5 billion global anaesthesia market. The deal is backed by a $2.5 million capital raising through a placement and rights offer, led by Peak Asset Management. …
Biotron to acquire Sedarex and raise $2.5 million to accelerate anaesthetic program
October 15, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech -
Novo Nordisk backs community-led initiative that aims to transform life for Logan’s children
February 18, 2026 - - Latest News -
CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy
February 18, 2026 - - Latest News -
Targeted blood cancer treatments proposed for funding in New Zealand
February 18, 2026 - - Latest News -
Percheron targets next wave of immunotherapy with novel VISTA checkpoint candidate
February 18, 2026 - - Australian Biotech